# US 7,611,707 B2 · Glycoprotein VI antibodies and methods thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 7,611,707 B2
- Document ID: US7611707B2
- Status: Granted
- Kind: B2
- Application number: 11/578,562
- Filed: 2005-04-26
- Published: 2007-08-30
- Granted: 2009-11-03
- Earliest claimed: 2004-04-29
- Assignees: Otsuka Pharmaceutical Co., Ltd.
- Inventors: Narendra Nath Tandon; Yutaka Matsumoto; Hisao Takizawa; Keiji Okuyama
- Web page: https://patentgrep.com/patent/US7611707B2

## CPC

- C07K 16/2803: {against the immunoglobulin superfamily}
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61K 2039/505: {comprising antibodies}
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/54: F(ab')2
- C07K 2317/55: Fab or Fab'
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention describes antibodies generated against platelet membrane glycoprotein VI-(GPVI), methods of producing the anti-GPVI antibodies, and the use of these antibodies as research and immunotherapeutic agents, in particular, as antithrombotic therapeutic agents.

## Claims

### Claim 1

A monoclonal antibody specific for a glycoprotein VI (GPVI) polypeptide or peptide, wherein the monoclonal antibody inhibits collagen-induced platelet aggregation at an IC50 of less than 7 μg/ml, wherein the IC50 is determined using a concentration of collagen that induces 70-90% platelet aggregation within 5 minutes of its contact with platelets in a platelet aggregation assay, wherein the monoclonal antibody specifically binds to a GPVI polypeptide or peptide at a Kd of lower than 10−8M, and wherein the monoclonal antibody is selected from OM1 (ATCC No. PTA-5938), OM2 (ATCC No. PTA-5939), OM3 (ATCC No. PTA-5940), and OM4 (ATCC No. PTA-5941).

### Claim 2 (depends on 1)

The monoclonal antibody of claim 1, wherein the monoclonal antibody is OM1.

### Claim 3 (depends on 1)

The monoclonal antibody of claim 1, wherein the monoclonal antibody is OM2.

### Claim 4 (depends on 1)

The monoclonal antibody of claim 1, wherein the monoclonal antibody is OM3.

### Claim 5 (depends on 1)

The monoclonal antibody of claim 1, wherein the monoclonal antibody is OM4.

### Claim 6 (depends on 1, 2, 3, 4, 5)

An antithrombotic composition comprising a pharmaceutically effective amount of at least one monoclonal antibody of claims 1-5 and a pharmaceutically acceptable excipient.

### Claim 7 (depends on 1, 2, 3, 4, 5)

A method of making an antithrombotic composition comprising admixing at least one monoclonal antibody of claims 1-5 in a pharmaceutically acceptable excipient.

### Claim 8 (depends on 1, 2, 3, 4, 5)

A kit comprising at least one dose of a pharmaceutically effective amount of at least one monoclonal antibody of claims 1-5 in a container.